Eli Lilly (LLY) on Solana

Eli Lilly has entered a global collaboration and license agreement with OmniAb to support a new ion channel drug discovery program, broadening Lilly's early-stage pipeline beyond its GLP-1 franchise. Under the deal, OmniAb will contribute its antibody discovery platform and ion channel expertise to drive the research program; the specific therapeutic target has not been disclosed.

Financial terms include an undisclosed upfront payment to OmniAb along with potential milestone payments of up to $370 million across research, development, and commercial stages, plus tiered royalties on global net sales. The partnership extends Lilly's strategy of sourcing early discovery capabilities externally while retaining global commercialization rights, and positions the company in the ion channel space where significant unmet medical needs remain.

Eli Lilly is pursuing a segmented obesity strategy built around matching drugs to patient profiles rather than competing on a single blockbuster. Zepbound, its weekly injectable GLP-1, remains the revenue anchor — along with diabetes drug Mounjaro, the two accounted for 65% of Q2 2026 revenue as quarterly sales grew 48% year-over-year to $23 billion. Foundayo, an oral anti-obesity pill approved in April 2026, targets injection-averse patients: the company says more than 80% of Foundayo prescriptions have gone to patients who had never taken a GLP-1 before, suggesting it is expanding the market rather than cannibalizing Zepbound.

Two pipeline candidates extend the coverage further. Retatrutide, a next-generation injectable showing superior weight-loss efficacy over Zepbound in phase 3 data, is already available through early access programs for patients with refractory obesity and at least two serious comorbidities; Lilly also cites A1C improvements in diabetic patients and benefits against obstructive sleep apnea and knee pain. Eloralintide takes a different mechanism altogether, mimicking the amylin hormone rather than GLP-1 pathways, and posted GLP-1-comparable weight-loss numbers with improved tolerability in phase 2 — positioning it for patients who experience significant gastrointestinal side effects on existing drugs. Lilly is also developing less-frequent-than-weekly dosing formulations and combination treatments for obesity patients with concurrent conditions such as psoriatic arthritis.

Eli Lilly's Q2 2026 earnings call — where the company reported $22.97 billion in revenue (a 47.7% year-over-year gain) and raised full-year guidance to an $86 billion midpoint — drew pointed analyst questions on the durability and strategic execution behind those numbers. Guggenheim's Seamus Fernandez pressed Lilly USA President Ilya Yuffa on how the company plans to sustain obesity market access gains, with Yuffa pointing to the Medicare Bridge program and LillyDirect as key consumer access levers. Goldman Sachs' Asad Haider asked how the newly launched oral GLP-1 Foundayo is tracking against Novo Nordisk's competing oral offering; management reported encouraging early uptake and cited supply chain advantages as a differentiator.

Beyond the incretin franchise, Bernstein's Courtney Breen asked about the regulatory timeline for retatrutide, with CEO David Ricks confirming that FDA submission is expected in early 2027. Jefferies' Akash Tewari questioned the implied deceleration in forward growth despite the strong beat, with CFO Lucas Montarce attributing it to one-off adjustments and seasonal effects rather than underlying demand. Evercore's Umer Raffat zeroed in on Zepbound net pricing, and Montarce acknowledged that medical exceptions providing price uplift are temporary, with the company expecting future volume growth to offset gradual price normalization.

The UK's Medicines and Healthcare products Regulatory Agency approved Foundayo (orforglipron) on August 11, 2026, making Britain the first European market to clear Eli Lilly's once-daily oral GLP-1 therapy. The pill is authorized for chronic weight management in adults with a BMI of 30 or higher — or 27 or higher with at least one weight-related comorbidity — as well as for insufficiently controlled type 2 diabetes. Dosing starts at 0.8mg and escalates in monthly steps to 17.2mg. Foundayo is initially available through private prescription while the National Institute for Health and Care Excellence conducts a benefit-cost review for potential NHS coverage. LLY shares rose roughly 3.9% on the news, and the drug is already approved in the US and UAE with EU, Japan, and Canada reviews pending.

The UK clearance puts Lilly directly alongside Novo Nordisk, whose oral semaglutide (Wegovy pill) launched in Britain about two months ago. Lilly is emphasizing a key convenience edge: Foundayo carries no food or water restrictions at the time of dosing, whereas Novo's oral Wegovy requires an empty stomach and a 30-minute waiting period before eating. That distinction could matter for adherence, though Foundayo's Q2 2026 global sales came in at $98 million — a figure analysts have described as modest relative to injectable GLP-1 volumes. The MHRA approval nonetheless marks the first step in a broader European expansion strategy for Foundayo, with the European Medicines Agency review still underway.

Eli Lilly's latest quarterly results have widened its competitive edge over Novo Nordisk in the GLP-1 drug market, with Lilly capturing 60.9% of the combined obesity and diabetes drug market in Q2 versus Novo's 38.8%. Booming demand for Mounjaro and Zepbound drove Lilly past second-quarter estimates and lifted its shares, while Novo Nordisk's stock fell after its own earnings raised concerns about pipeline clarity and long-term growth prospects — even as Novo raised its guidance.

Analysts are increasingly skeptical of Novo's path forward. BMO Capital Markets analyst Evan Seigerman noted that "while Novo raised guidance (as expected), the pipeline and path to sustainable growth remain less clear." The gap matters because the global GLP-1 market is projected by some analysts to exceed $100 billion annually by the 2030s — a prize large enough that the distance between the two companies, measured in market share and investor confidence, carries significant consequence for both.

Eli Lilly reported Q2 2026 revenue of $22.97 billion, up 48% year over year and well ahead of the roughly $20 billion Wall Street consensus, as its two flagship GLP-1 drugs continued to dominate the obesity and diabetes market. Adjusted EPS came in at $8.38, topping analyst estimates near $6.01. Mounjaro, the tirzepatide diabetes treatment, generated $9.94 billion in quarterly revenue — a 91% increase from a year earlier — while Zepbound, the obesity-indicated formulation, contributed approximately $4.93 billion. Together the two drugs accounted for $14.87 billion, or roughly 65% of total quarterly revenue, materially widening Lilly's lead over Novo Nordisk. U.S. revenue reached $14.4 billion (up 33% YoY), with international sales of $8.6 billion growing 80% in reported terms driven by 113% volume growth.

The company raised its full-year 2026 revenue guidance to $85 billion to $87 billion, up from the prior range of $82 billion to $85 billion, and lifted its adjusted non-GAAP EPS outlook by roughly $2.78 per share at the midpoint. Foundayo, Lilly's oral obesity pill, generated $98 million in the quarter, slightly below the $103 million analyst estimate. Lilly also announced $4.5 billion in new Indiana manufacturing capital expenditure to scale production of Foundayo and retatrutide. Shares rose more than 5% following the report.

The FDA has granted Breakthrough Therapy designation to Eli Lilly's olomorasib for KRAS G12C-mutant advanced pancreatic cancer, the second such designation the KRAS inhibitor has received across cancer indications. The status, reserved for investigational drugs that show preliminary clinical evidence of substantial improvement over existing therapies in serious conditions, accelerates development and review timelines and gives Lilly deeper regulatory engagement as it builds a credible oncology pipeline alongside its dominant obesity and diabetes franchise.

The designation strengthens the valuation case for LLY at a moment when the stock has come under pressure — down roughly 8.6% over the prior week — partly on concerns about GLP-1 pricing and competitive dynamics. Analysts tracking the name estimate fair value near $1,477, a roughly 24% premium to recent trading levels around $1,116, with the argument that Lilly's most consequential pipeline assets are not yet approved and thus not yet reflected in revenue. Olomorasib's progress into a second high-need oncology indication adds another potential revenue leg that could support that thesis if clinical data hold and approval timelines compress under Breakthrough status.

Goldman Sachs maintained its Buy rating on Eli Lilly (LLY) ahead of Q2 2026 earnings, setting a 12-month price target of $1,283 — roughly 7% above the July 24 close of $1,196.03 — but the note carries pointed caution. The bank projects Q2 revenue of $20.8 billion and adjusted EPS of $5.83, and frames "the size of Lilly's next guidance raise" as "the single most important variable for how the stock reacts," modeling a potential lift to $86.1 billion from the current $83–85 billion annual range. Goldman sees international Mounjaro as the primary profit engine, forecasting $4.95 billion in outside-the-U.S. Q2 sales — roughly 10% above consensus — and notes the drug holds about 60% of the incretin market in Brazil and Korea.

Offsetting that optimism, Goldman sharply cut its Foundayo outlook, projecting only $40 million in Q2 U.S. sales against a $100 million consensus after five consecutive weeks of stalled weekly prescriptions, and slashed its full-year 2026 U.S. estimate from $1.1 billion to $755 million. The bank also called U.S. pricing — down 13% in Q1 2026 despite a volume surge — "the risk to be most cautious about," while a retatrutide filing delay pushed to Q1 2027 and the possibility of large employers dropping GLP-1 coverage in 2027 add further uncertainty to Lilly's longer-term trajectory.

Novo Nordisk filed a lawsuit against Eli Lilly in U.S. District Court in New Jersey on July 21, alleging that advertising campaigns for Lilly's Zepbound and Mounjaro are "maliciously and deceptively false." The central claim is that Lilly's ads — which ran during major global sporting broadcasts and on TikTok and Facebook — compare the highest available doses of its own drugs against lower, older doses of Novo's Wegovy and Ozempic, while no head-to-head trial has ever tested the highest doses of both medicines against each other. Novo is seeking a permanent injunction to pull Lilly's comparative ad campaigns and compel a corrective advertising push; if Lilly does not comply voluntarily, Novo says it will seek a preliminary injunction to block the ads while the case proceeds.

The lawsuit puts direct pressure on the marketing engine behind two of Lilly's most important revenue drivers. Mounjaro and Zepbound together account for roughly two-thirds of Lilly's total revenue, with Mounjaro alone recently posting 125% year-over-year growth. Lilly defended its advertising, stating that it "is truthful, it is transparent, and it is grounded in the most direct scientific evidence available," and pointed to its Surmount-5 head-to-head trial as the gold standard for comparing the medicines. A court order requiring Lilly to withdraw or materially alter its comparative GLP-1 campaigns would represent a meaningful constraint on the aggressive marketing positioning that has underpinned the drugs' commercial momentum.

Viking Therapeutics announced on June 24 the start of a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist targeting obesity through a mechanism outside the GLP-1 pathway. Amylin is a pancreatic hormone that promotes satiety and slows gastric emptying; preclinical data showed up to 8% weight reduction against controls. The candidate is positioned as a potential complement or alternative to existing GLP-1 drugs, but it enters a field where Eli Lilly and Novo Nordisk have already built commanding leads.

Eli Lilly's own amylin candidate, eloralintide, reported Phase 2 results in November 2025 showing mean weight reductions of 9.5% to 20.1% over 48 weeks against 0.4% with placebo, and Phase 3 enrollment is already underway — including a combination trial pairing eloralintide with Lilly's tirzepatide (Mounjaro/Zepbound). Novo Nordisk's cagrilintide similarly entered Phase 3 in late 2025, and CagriSema — cagrilintide combined with semaglutide — was submitted to the FDA in December for a 2026 review. Viking's Phase 1 trial puts VK3019 roughly three to four years behind both incumbents on the amylin pathway, suggesting the competitive threat to Lilly's weight-loss franchise is limited in the near term.